Maravai LifeSciences Holdings Inc. Class A Common Stock vs VanEck Rare Earth/Strategic Metals — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while VanEck Rare Earth/Strategic Metals trades at $54.5 (market cap $1.64B). The key difference: VanEck Rare Earth/Strategic Metals is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and VanEck Rare Earth/Strategic Metals for 52 Days on average.
| MRVI | REMX | |
|---|---|---|
Market Cap | $972.90M | $1.64B |
Volume | 4,325,710 | 710,568 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $109.53 |
52-Week Low | $2.83 | $55.78 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $1.08B | — |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $57.45, down 1.25% amid bearish technical signals with moving averages indicating strong selling pressure. The ETF provides exposure to 38 global rare earth companies but faces high volatility and China concentration risks. Recent institutional activity includes Bank of America increasing its position by 72.1% in Q2 2026, while geopolitical developments around critical minerals supply chains continue to influence sentiment.
The outlook remains challenged by technical weakness and sector volatility, though oversold RSI readings suggest potential near-term bounce. Long-term prospects hinge on U.S. supply chain development and China export policies, but the ETF's 50% annualized volatility makes it unsuitable for conservative investors. Strategic importance of rare earths supports thematic interest despite execution risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →